Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q4 2017 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$3.85M$3.85Mderived−26.9% vs Q4 2016 Net Income-$13.83M-$13.83MderivedN/M vs Q4 2016 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$680,801−61.0% Operating Incomederived-$13,690,573N/M Operating Cash Flowderived$936,763−36.4% Free Cash Flowderived$867,608−36.5% Margins · derivedGross margin17.7%−15.5 pt vs Q4 2016
Operating margin-355.8%−297.6 pt vs Q4 2016
Net margin-359.4%−294.3 pt vs Q4 2016
ended Dec 31, 2017 · filed Apr 2, 2018 · 92 d after period end